Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to early-stage innovators DUBLIN and CHESHIRE, England, Feb. 24, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results